Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: A case series

British Journal of Cancer

Volumn 115, Issue 11, 2016, Pages 1280-1284

  Carlino, Matteo S ^a,b   Vanella, Vito ^c   Girgis, Christina ^b   Giannarelli, Diana ^d   Guminski, Alex ^a,e   Festino, Lucia ^c   Kefford, Richard F ^a,b,f   Menzies, Alexander M ^a,e   Long, Georgina V ^a,e   Ascierto, Paolo A ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Crown Princess Mary Cancer Centre Westmead   (Australia)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; ENCORAFENIB; IPILIMUMAB; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NIVOLUMAB; PEMBROLIZUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CASE STUDY; CLINICAL ARTICLE; CLINICAL OUTCOME; COMPASSIONATE USE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; METASTATIC MELANOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PANCREAS CANCER; PARADOXICAL DRUG REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; GENETICS; MELANOMA; MUTATION; RECURRENT DISEASE; SURVIVAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECURRENCE; SURVIVAL ANALYSIS;

EID: 84990177799     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.321     Document Type: Article

References (21)

1. Beda M, Basso U, Ghiotto C, Monfardini S (2007) When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? Tumori 93(5): 491-492.
2. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group J Clin Oncol 25(9): 1107-1113.
3. Carlino MS, Kwan V, Miller DK, Saunders CA, Yip D, Nagrial AM, Tomlinson J, Grimmond SM, Scolyer RA, Kefford RF, Biankin AV, Long GV (2014) New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J Clin Oncol 33: e52-e56.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507-2516.
5. Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J (2012) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 23(7): 1788-1795.
6. Gullo G, Zuradelli M, Sclafani F, Santoro A, Crown J (2012) Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol 23(8): 2204-2205.
7. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller Jr WH, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839): 358-365.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8): 711-723.
9. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegard T, Reichardt P (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12): 1265-1272.
10. Klein O, Ribas A, Chmielowski B, Walker G, Clements A, Long GV, Kefford RF (2013) Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol 31(12): e215-e217.
11. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20): 1867-1876.
12. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1): 23-34.
13. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandala M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20): 1877-1888.
14. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris 3rd HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT (2016) Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34(8): 871-878.
15. Menzies AM, Kefford RF, Long GV (2013) Paradoxical oncogenesis: are all BRAF inhibitors equal? Pigment Cell Melanoma Res 26(5): 611-615.
16. Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV (2015) Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 121(21): 3826-3835.
17. Paraiso KHT, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson ARA, Ribas A, Dalla Palma M, Nathanson KL, Koomen JM, Messina JL, Smalley KSM (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71(7): 2750-2760.
18. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu W-J, Weber JS, Gangadhar TC, Joseph RW, Dronca RS, Patnaik A, Zarour HM, Kefford R, Hersey P, Li X, Diede SJ, Ebbinghaus S, Hodi FS (2016) Threeyear overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol (suppl; abstr 9503).
19. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A. KEYNOTE-006 investigators (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26): 2521-2532.
20. Tolk H, Satzger I, Mohr P, Zimmer L, Weide B, Schad S, Gutzmer R (2015) Complete remission of metastatic melanoma upon BRAF inhibitor treatment-what happens after discontinuation? Melanoma Res 25(4): 362-366.
21. Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ (2015) Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther 16(5): 662-670.